Neoadjuvant chemotherapy in the management of cervical cancer. A long and winding road. State of the art

Cervical cancer; Neoadjuvant chemotherapy; Radical surgery

[1] Soderini A, Aragona A, CuneoN. The problem of cervical cancer. Actual Experiences in Gynecology Oncology (pp. 25–30). 3rd edn. Ascune Editors: Buenos Aires. 2024.

[2] Soderini A, Reyes C. Module 3: chapter 16. Invasive carcinoma of the cervix. E-Book textbook of Gynecology Oncology (pp. 60–74). 1st edn. Ascune Editors: Buenos Aires. 2020.

[3] Aragona A, Soderini A, Moschen H, Bonavia E, Garrido R, Cúneo N. High mortality for cervical cancer in young women from the metropolitan area of Buenos Aires. Medicina. 2018; 78: 234–242.

[4] Soderini A. The cervical cancer. Handbook of practical management guidelines of genital and breast cancer (pp. 63–74). 1st end. Ascune Editors: Buenos Aires. 2022.

[5] Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermúdez A, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecologic Oncology. 1997; 67: 61–69.

[6] Pecorelli S, Odicino F. Cervical cancer staging. The Cancer Journal. 2003; 9: 390–394.

[7] Sardi J E, Sananes CE, Giaroli AI, Bermudez A, Ferreira MH, Soderini AH, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. International Journal of Gynecological Cancer. 1998; 8: 441–450.

[8] Sardi J, Giaroli A, Sananes C, Rueda NG, Vighi S, Ferreira M, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management. International Journal of Gynecological Cancer. 1996; 6: 85–93.

[9] Etcheverry MG, Marantz AT, Saine M, Litovska ST, Lewi DT, Cecchin G, et al. Neoadjuvant chemotherapy with cisplatin, ifosfamide and 5-fluorouracil in the treatment of locally advanced cervical cancer. International Journal of Gynecological Cancer. 2000; 10: 53–58.

[10] Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiationtherapy for bulky stage IB and IIA cervical cancer. Journal of Clinical Oncology. 2000; 18: 1740–1747.

[11] Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology. 2002; 20: 179–188.

[12] Neoadjuvant chemotherapy for locally advanced cervical cancer meta-analysis collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. European Journal of Cancer. 2003; 39: 2470–2486.

[13] Choi YS, Sin JI, Kim JH, Ye GW, Shin IH, Lee TS. Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. Journal of Korean Medical Science. 2006; 21: 683–689.

[14] Guo L, Liu X, Wang L, Sun H, Huang K, Li X, et al. Outcome of international federation of gynecology and obstetrics stage IIB cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study. International Journal of Gynecological Cancer. 2015; 25: 910–918.

[15] Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database of Systematic Reviews. 2010; 20: CD007406.

[16] Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. European Journal of Surgical Oncology. 2013; 39: 115–124.

[17] Chou HH, Huang HJ, Lin H, Yang LY, Hsueh S, Liu FY, et al. Phase I dose-escalation study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer. American Journal of Clinical Oncology. 2017; 40: 241–249.

[18] Zanaboni F, Grijuela B, Giudici S, Cormio G, Babilonti L, Ghezzi F, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study. European Journal of Cancer. 2013; 49: 1065–1072.

[19] Benedetti PP, Palaia I, Marchetti C, Ruscito I, Fischetti M, Musella A, et al. Dose dense neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: a phase II study. Oncology. 2015; 89: 103–110.

[20] Chuang L, Feldman S, Nam Joo-Hyun, Thomas G, Bereck J. SGO-ASCO new clinical practice guideline. 2016. Available at: www.asco.org (Accessed: 02 June 2016).

[21] Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, et al. Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2–IIB cervical cancer: EORTC-55994. Journal of Clinical Oncology. 2023; 10: 5503–5503.

[22] Sardi J, Sananes C, Giaroli A, Gomez Rueda N, Di Paola G, Vighi S, et al. Is subradical surgical treatment for carcinoma of the cervix uteri stage IB logical? Gynecologic Oncology. 1989; 32: 360–364.

[23] Ferreyra M, Soderini A, Sardi J. Subradical treatment for carcinoma of the cervix IB, Dogma or utopia? European School of Oncology in the First Latin-American Educational Convention. ESO: Buenos Aires. 1995.

[24] Landoni F, Parma G, Peiretti M, Zanagnolo V, Sideri M, Colombo N, et al. Chemo-conization in early cervical cancer. Gynecologic Oncology. 2007; 107: S125–S126.

[25] Lanowska M, Mangler M, Speiser D, Bockholdt C, Schneider A, Köhler C, et al. Radical vaginal trachelectomy after laparoscopic after laparoscopic staging and neoadjuvant chemotherapy in women with early stage cervical cancer over 2 cm: oncologic, fertility and neonatal outcome in a series of 20 patients. International Journal of Gynecological Cancer. 2014; 24: 586–593.

[26] Plante M. Bulky early-stage cervical cancer (2–4 cm lesions): upfront radical trachelectomy or neoadjuvant chemotherapy followed by fertility-preserving surgery: which is the best option? International Journal of Gynecological Cancer. 2015; 25: 722–728.

[27] Soderini A, Aragona A, Bonavia E, Moschen H, Mendez M, Garrido R, et al. Neoadjuvant chemotherapy (NCH) followed by abdominal radical trachelectomy (ART) in cervical cancer: long term follow up results of the Buenos Aires experience. Journal of Advanced Surgical Research. 2017; 1: 7–12.

[28] Rendón GJ, Lopez Blanco A, Aragona A, Saadi JM, Di Guilmi J, Arab Eblen C, et al. Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm. International Journal of Gynecological Cancer. 2021; 31: 462–467.

[29] Soderini A, Giaroli A, Sananes C, Anchezar JP, Alessandría S, Sardi J. Nowadays in pelvic exenterations (PE). Long term follow-up. The Buenos Aires experience. International Journal of Gynecological Cancer. 2004; 14: 54.

[30] Benedetti Panici P, Bellati F, Manci N, Pernice M, Plotti F, Di Donato V, et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer. Annals of Surgical Oncology. 2007; 14: 2643–2648.

[31] Landoni F, Zanagnolo V, Rosenberg PG, Lopes A, Radice D, Bocciolone L, et al. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: single institution experience. Gynecologic Oncology. 2013; 130: 69–74.

[32] Angioli R, Soderini A, Plotti F, Damiani P, Montera R, Capriglione S, et al. Surgical primary treatment of stage IVA cervical cancer: a multicentre retrospective study. Gynecologic Oncology. 2012; 125: S52.

[33] Sananes C, Giaroli A, Soderini A, Guardado N, Snaidas L, Bermudez A, et al. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvantchemotherapy in the treatment of carcinoma of the cervix uteri: long-term follow-up of a pilot study. European Journal of Gynaecological Oncology. 1998; 19: 368–373.

[34] Angioli R, Plotti F, Montera R, Aloisi A, Luvero D, Capriglione S, et al. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecologic oncology. 2012; 127: 290–296.

[35] McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study ofweekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. British Journal of Cancer. 201; 108: 2464–2469.

[36] McCormack M, Gallardo Rincón D, Eminowicz G, Diez P, Farrelly L, Kent C, et al. LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial. Annals of Oncology. 2023; 34: S1254–S1335.

[37] Soderini A, Aragona A, Quintaie A, Moschen H, Mendez M. Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: what should we do with the FIGO staging system and therapeutic strategies? Archives of Cancer Science and Therapy. 2021; 5: 002–005.

[38] Depietri V, Aragona A, Crespe M, Soderini A. Stages of cervical cancer at the first appoiment in a public oncologic hospital of the city of Buenos Aires: period 2019–2022, from normality to pandemia. Revista SOGBA. 2023; 54: 20–43. (In Spanish)

[39] Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics. 2018; 2: 22–36. Erratum in: International Journal of Gynaecology and Obstetrics. 2024; 164: 1229–1230.

[40] Spreafico A, Sultanem K, Chen B, Bratman SV, Ringash J, Louie AV, et al. A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by Adjuvant tremelimumab and durvalumab in intermediate risk HPV-positive. Locoregionally Advanced Oropharyngeal Squamous Cell Cancer. 2018; 29: viii399.

[41] Fracasso PM, Duska LR, Thaker PH, Gao F, Zoberi I, Dehdashti F, et al. An exploratory study of neoadjuvant cetuximab followed by cetuximab and chemoradiotherapy in women with newly diagnosed locally advanced cervical cancer. American Journal of Clinical Oncology. 2022; 45: 286–293.

[42] Soderini A, Montera R, Aragona A. Neoadjuvant chemotherapy in cervical cancer: from yesterday to today. International Gynecologic Cancer Society Annual Meeting. 2019. Available at: www.ijgc.org/www.igcs.org/ (Accessed: 19 September 2019).

[43] Cervical cancer. NCCN (National Comprehensive Cancer Network) clinical practice guidelines in oncology. 2021. Available at: www.nccn.org (Accessed: 26 October 2021).